A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 25, 2007

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

ABT-263

Tablet; Oral

Trial Locations (10)

3000

Peter MacCallum Cancer Ctr /ID# 6583, Melbourne

3050

The Royal Melbourne Hospital /ID# 5576, Parkville

11040

North Shore University Hospital /ID# 12267, New Hyde Park

50937

Universitaetsklinikum Koeln /ID# 5924, Cologne

68198

University of Nebraska Medical Center /ID# 12261, Omaha

77030

University of Texas MD Anderson Cancer Center /ID# 5575, Houston

92093

Moores Cancer Center at UC San Diego /ID# 5566, La Jolla

98405

Northwest Medical Specialties - Tacoma /ID# 26428, Tacoma

02215

Dana-Farber Cancer Institute /ID# 5547, Boston

LE1 5WW

Leicester Royal Infirmary /ID# 15081, Leicester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

AbbVie

INDUSTRY